Finally, drugs such as the tyrosine kinase inhibitor dasatinib have been shown to inhibit CLL cell migration and signaling to AKT by blocking SDF-1 signaling [35]. The gene discussed is AKT1; the disease is B-cell chronic lymphocytic leukemia.